Please login to the form below

Not currently logged in
Email:
Password:

UK biotech

This page shows the latest UK biotech news and features for those working in and with pharma, biotech and healthcare.

UK biotech Synairgen treats first patient in phase 3 COVID-19 trial

UK biotech Synairgen treats first patient in phase 3 COVID-19 trial

UK biotech company Synairgen has treated the first patient in a phase 3 trial evaluating its potential COVID-19 treatment SNG001. ... We believe this trial presents an opportunity for a significant UK scientific breakthrough and, if given the right

Latest news

More from news
Approximately 27 fully matching, plus 163 partially matching documents found.

Latest Intelligence

  • Setting up for success in a post-Brexit, post-pandemic Britain Setting up for success in a post-Brexit, post-pandemic Britain

    Creating a new biotech affiliate and seeking marketing authorisation for a new drug in the UK during a pandemic. ... With three COVID-19 vaccines approved for use in the UK at the time of publication, positive NICE recommendations for medicines like

  • A snapshot of… Enterprise Therapeutics A snapshot of… Enterprise Therapeutics

    We tend to experience the same challenges that all small biotech companies do – how do we ensure our therapies have the best chance of making it through to registration against a ... companies. However, it remains to be seen what effects Brexit may

  • A snapshot of Healx A snapshot of Healx

    Healx is based in Cambridge, UK, a key European biotech hub, and was founded in 2014 by Dr Tim Guilliams, a biochemical engineer and founder of the Cambridge Rare Disease Network, ... Why will the company make it in the high-risk, highly competitive

  • A snapshot of Microbiotica A snapshot of Microbiotica

    Why will Microbiotica make it in the high-risk, highly competitive biotech field? ... Of greater concern is the university sector – the UK biotech sector is what it is because of the increasing excellence of the university sector over the last 20 years.

  • Building European biotech firms to rival those of the US Building European biotech firms to rival those of the US

    Richard Mason (pictured above) is a veteran of the UK biotech industry, including a spell as CEO of company XO1 set up by venture capital investors Index Ventures (now Medicxi) in ... In the early days of UK biotech, this often led to major upfront

More from intelligence
Approximately 1 fully matching, plus 19 partially matching documents found.

Latest appointments

  • F-star hires ex-BMS immuno-oncology leader

    New CMO to oversee development of lead candidate. UK biotech F-star has appointed Louis Kayitalire, MD, as its new Chief Medical Officer (CMO), wooing him from a senior role in ... F-star says this newly created management position will be crucial

  • Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO

    Latest movers in pharma and biotech. Immunocore names new CEO. Bahija Jallal, Immunocore's next CEO. ... Immunotherapy-focused UK biotech company Immunocore has unveiled Bahija Jallal as its new chief executive and director of the board.

  • Redx poaches AstraZeneca senior executive Redx poaches AstraZeneca senior executive

    Lisa Anson joins the UK biotech as its CEO. Drug discovery and development group Redx Pharma has appointed its new chief executive officer in the form of Lisa Anson. ... substantial biotech company built upon an innovative science base, selectively

  • Redx Pharma appoints new chief medical officer Redx Pharma appoints new chief medical officer

    Dr Andrew Saunders joins the UK biotech from Lytix Biopharma. Drug discovery and development group Redx Pharma has appointed Dr Andrew Saunders as its chief medical officer (CMO), a role that ... He joins the UK biotech from Lytix Biopharma, a Norweigan

  • Glythera strengthens its scientific advisory board and appoints CSO Glythera strengthens its scientific advisory board and appoints CSO

    Dr Robert Lutz and Dr Jon Roffey join the UK biotech. ... Glythera has appointed new chief scientific officer Dr Robert Lutz to lead the advancement of the UK-based biotech's antibody drug conjugate portfolio.

More from appointments
Approximately 2 fully matching, plus 27 partially matching documents found.

Latest from PMHub

  • Lucid bolsters its senior leadership team

    Shula began working in medical communications in the USA following a successful research career in academia and the biotech industry in the UK, Germany and the USA. ... Coming back to the UK after 13 happy and successful years in America has given me the

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Guide
How to embrace behavioural science principles in healthcare MR...
Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...